Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels

Fertility and Sterility

Volumn 69, Issue 5, 1998, Pages 876-882

  Mijatovic, Velja ^a   Kenemans, Peter ^a   Netelenbos, Coen ^a   Jakobs, Cornelis ^a   Popp Snijders, Corrie ^a   Peters Muller, Edith R ^a   Van Der Mooren, Marius J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dydrogesterone; Estradiol; Homocysteine; Hormone replacement therapy; Postmenopausal

Indexed keywords

DYDROGESTERONE; ESTRADIOL; FOLLITROPIN; HOMOCYSTEINE; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; MIDDLE AGED;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOMOCYSTEINE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN;

EID: 0032056407     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00041-7     Document Type: Article

References (25)

1. 1. Clarke L, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
2. 2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
3. 3. Ueland PM, Refsum H, Stabler SP, Manilow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-79.
4. 4. Manilow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994;236:603-17.
5. 5. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences. Q J Med 1993;86:685-9.
6. 6. Van den Berg M, Boers GH. Homocystinuria: what about mild hyperhomocysteinaemia? Postgrad Med J 1996;72:513-8.
7. 7. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983;72:1971-6.
8. 8. Wouters MGAJ, Moorees MThEC, Van der Mooren MJ, Blom HJ, Boers GHJ, Schellekens LA, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-5.
9. 9. Brattstrom LE, Hultberg B, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985;34:1073-7.
10. 10. Van der Mooren MJ, Wouters MGAJ, Blom HJ, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-6.
11. 11. Van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Homocysteine concentrations may decrease during postmenopausal hormone replacement therapy. Ir J Med Sci 1995; 164(Suppl 15):21.
12. 12. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991;20:47-63.
13. 13. Pines A, Mijatovic V, Van der Mooren MJ, Kenemans P. Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol 1997;71:193-7.
14. 14. Whitehead MI, Hillard T, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75:59S-76S.
15. 15. Rijpkema AHM, Van der Sanden AA, Ruijs AHC. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12:259-85.
16. 16. Crook D, Godsland IF, Stevenson JC. The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review. Eur Menopaus J 1995;2(Suppl 4):23-30.
17. 17. Ubbink JB, Vermaak WHJ, Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441-6.
18. 18. Thomas CMG, Van den Berg RJ, Segers MFG, Bartelink ML, Thien T. Inaccurate measurements of 17β-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17β-oestradiol. Clin Chem 1993;39:2341-2.
19. 19. Voetberg GA, Netelenbos JC, Kenemans P, Peters-Muller ERA, Van de Weijer PHM. Estrogen replacement therapy continuously combined with four dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994;79:1465-9.
20. 20. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
21. 21. Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995;60:365-8.
22. 22. Blom HJ, Boers GHJ, Van den Elzen PAM, Van Roessel JJM, Trijbels JMF, Tangerman A. Differences between premenopausal women and young men in the transamination pathway of methionine catabolism, and the protection against vascular disease. Eur J Clin Invest 1988;18: 633-8.
23. 23. Van der Mooren MJ, Demacker PNM, Blom HJ, de Rijke YB, Rolland R. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril 1997;67:67-73.
24. 24. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
25. 25. Manolio TA, Furberg CD, Schemanski L, Psaty BM, O'Leary DH, Tracy RP, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993;88:2163-71.